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The metabolic syndrome, a cluster of insulin resistance, elevated blood pressure, and atherogenic dyslipidemia, is a common 
basis of atherosclerosis. Accumulation of intra-abdominal visceral fat stands upstream of the metabolic syndrome. Adipose tissue 
expresses a variety of genes for bioactive secretory proteins conceptualized as adipocytokines. We discovered a novel adipose-
specific protein named adiponectin from human fat cDNAs. Adiponectin circulates in the plasma and its serum level is decreased
in visceral fat accumulation. Results of experimental and clinical researches have demonstrated that hypoadiponectinemia 
underlies the pathogenesis of multiple diseases related to visceral fat accumulation, including atherosclerosis, hypertension, 
cardiac failure, insulin resistance, diabetes, hepatic steatosis, inflammatory bowel disease, and cancers. Recently, we revealed
fat-derived reactive oxygen species (fat ROS) as an upstream factor in the development of hypoadiponectinemia and metabolic 
syndrome.  Intervention targeting visceral fat accumulation, hypoadiponectinemia and fat ROS should be the way to therapeuti-
cally tackle the metabolic syndrome.  Biomed Rev 2006; 17: 1-10.
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INTRODUCTION
Metabolic syndrome (MetS) is the pathologic condition 
coexisting several risk factors for cardiometabolic diseases, 
including atherosclerosis, hypertension, type 2 diabetes, and 
dyslipidemia (1). From our and others’ clinical works, it is 
revealed that distribution of body fat more strongly associ-
ates with the development of MetS, than absolute amount of 
body fat, i.e. obesity (2-6). Recently, the diagnostic criteria 
of MetS is defined globally (1). It includes increase of waist
circumference, good indicator for visceral fat accumulation, 
as a necessary component, and additional 2 or 3 risk factors. 
There has been a growing evidence that adipose tissue is a huge 
endocrine organ to produce and secrete a varieties of biological 
active substances which we conceptualised as adipocytokines 
(7,8). Dysregulated productions of adipoctytokines in visceral 
fat obesity lead to the development of MetS. Adiponectin is 
one of adipocytokines we discovered from human adipose 
cDNAs (9,10). 
Here we summarize the historical movement that led to the 
concept of MetS and adipocytokines. Especially, we put a high 
tension on the role of adiponectin both in the pathogenesis and 
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the therapy of MetS. We also highlight our recent progress 
featuring the significance of fat-derived reactive oxygen spe-
cies (fat ROS) as an upstream factor in the development of 
hypoadiponectinemia and MetS. Reduction of visceral fat, 
improvement of hypoadiponectinemia, and decreasing fat ROS 
should be now being recognized in the prevention and cure of 
MetS and its associated cardiometabolic diseases.
CONCEPT OF METABOLIC SYNDROME
Multiple risk factor syndrome is a cluster of hyperglycemia, 
hypertriglyceridemia, increased level of low high-density 
lipoprotein (HDL) cholesterol and high blood pressure in an 
individual. Historically, the similar concepts were proposed 
as “syndrome X” by Reaven (11), “deadly quartet” by Kap-
lan (12), “insulin resistance syndrome” by De Fronzo (13), 
and “visceral fat syndrome” by Matsuzawa (14). Syndrome 
X and insulin resistance syndrome were based on existence 
of insulin resistance as a common upstream feature. Deadly 
quartet pointed the significance of abdominal obesity, as well 
as glucose intolerance, hypertriglyceridemia, and hyperten-
sion, whereas visceral fat syndrome, for the first time, put the
visceral fat accumulation as a necessary upstream component 
in the syndrome’s pathogenesis similarly to the concept of 
MetS currently defined.
 During the early 1980’s, our group introduced computer tom-
ography (CT) scan method to evaluate the amount of adipose 
tissue associated with obesity (4). The assessment of the total 
amount of subcutaneous fat by this method did not provide 
any additional information on obesity-related diseases beyond 
body mass index (BMI). However, subjects predominantly 
with intra-abdominal visceral fat excess were revealed to 
have glucose intolerance, dyslipidaemia and hypertension 
more frequently, as compared to those with subcutaneous fat 
accumulation. These results reached the concepts of visceral fat 
type obesity (VFO) and subcutaneous fat type obesity (SFO) 
(Fig. 1). Furthermore, approximately 40% of the patients with 
cardiovascular disease (CVD), irrelevant to obesity or not, 
was shown to have visceral fat accumulation, accompanied 
by multiple coronary risk factors (5). Thus, we conceptualized 
this pathogenetic condition as visceral fat syndrome, almost 
identical to the MetS currently defined.
CONCEPT OF ADIPOCYTOKINES
To elucidate the missing link between visceral fat accumula-
tion and the development of the clustering of multiple risk 





Figure 1. Visceral fat type obesity (VFO) and subcutaneous fat type obesity (SFO) are assessed by computed tomograpy (CT) 
at umbilicus level. VFO is more associated with various obesity-related complications, such as insulin resistance, diabetes, 
dyslipidemia, hypertension, and coronary artery disease, than SFO.
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expression profiles in human adipose tissues, and compared 
the data with the results obtained from the similar analysis of 
other human tissues and organs in the projects called Body 
Mapping (9). The results from Body Mapping revealed that 
adipose tissues, especially visceral fat, abundantly expressed 
a variety of genes for secretory proteins. Around 30 % of 
the genes expressed in human visceral fat tissue and 20 % in 
human subcutaneous fat tissue coded the genes for secretory 
proteins. It was shown that adipose tissues expressed the 
mRNAs for secretory proteins abundantly among the dozens 
of human tissues and organs analysed. We found plasminogen 
activator inhibitor type 1 (PAI-1) and heparin binding EGF-
like growth factor (HB-EGF) in visceral fat cDNA library. Our 
subsequent study showed that accumulated visceral adipose 
tissue overproduces and secretes PAI-1, which in turn raises 
the risk for thrombotic disorders (7). These were the first ex-
amples recognizing adipose tissue-derived secretory factors 
as direct modulators of vascular biology. We conceptulaized 
such factors as adipocytokines (7). 
Adiponectin  
Identification and significance
In Body Mapping, we discovered a novel gene encoding 
adipocyte-derived secretory protein, lately named adiponec-
tin (10). Adiponectin was expressed exclusively and most 
abundantly in adipose tissue. The molecule has two domains, 
a collagen-like fibrous and C1q-like globular domains. Single
molecules bind together and form a high-ordered structure (15). 
We established ELISA system to measure plasma adiponectin 
levels in human subjects. There were two surprising facts we 
were faced by in the initial studies: (i) plasma adiponecitn 
levels were extremely high up to 5-20 μg/ml in healthy hu-
mans, and (ii) plasma adiopnectin levels decreased with the 
accumulation of body fat, especially visceral fat, while the 
blood concentrations of other adipocytokines known to date, 
like leptin and PAI-1, increased in parallel with fat accumula-
tion in body. Following numerous studies have revealed that 
decreased plasma adiponectin (hypoadiponectinemia) associ-
ated with visceral fat accumulation is an upstream pathological 
condition of many diseases (Fig. 2). 
Figure 2. Hypoadiponectinemia associated with visceral fat accumulation is located at upstream of various lifestyle-related 
diseases, including diabetes, hypertension, dyslipiedemia, and atherosclerosis. Recent works revealed the association of hypoadi-
ponectinemia with the pathogenesis of heart failure, hepatic steatosis, and various cancers.
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DISEASES FEATURED BY ADIPONECTIN DEFICIT 
Atherosclerosis
Our very initial study showed recombinant adiponectin protein 
bound tightly to collagens I, III, and V, which were known to 
present in the subendothelial intima (16). Following in vivo 
analysis found that adiponectin adhered subendotherial space 
in the endothelium-injured arterial walls. Further clinical study 
showed that plasma adiponectin levels were significantly
lower in subjects with CVD, as compared with BMI-matched 
controls (17). Experimentally, we treated the recombinant 
adiponectin protein on various types of vascular cells. Admin-
istration of adiponectin suppressed (i) TNFα-induced expres-
sion of adhesion molecules in the vascular endothelial cells 
by inhibiting nuclear translocation of NF-κB (2,17,18), (ii) 
growth factor-induced proliferation and migration of smooth 
muscle cells by inhibiting mitogen activated protein (MAP) 
kinase pathway (3,19), and (iii) foam cell transformation of 
the macrophages by inhibiting the expression of scavenger 
receptor (20). These data suggested that circulating adiponectin 
accumulates in the places where the endothelial barrier is dam-
aged, and has protective effects against the series of process for 
the development of atherosclerosis. To confirm this concept,
we generated mice disrupting adiponectin gene. When the 
vascular walls of adiponectin-knockout (APN-KO) mice were 
injured by catheter wire, they exhibited severer neointimal 
thickening (21). Adiponecitn overproduction using adenovirus 
decreased the size of lipid droplets in the fatty-streak lesion and 
atherosclerotic plaque in apolipoprotein E-deficient mice (22).
These were accompanied by reduced expression of mRNAs of 
VCAM-1, class A scavenger receptor, and TNF-α in the aorta. 
These results confirmed the pivotal role of adiponectin deficit
in the development of atherosclerosis in animal model. 
In human study, subjects with plasma adiponectin levels 
less than 4 μg/ml reached twice high incidence for CVD, as an 
independent factor (23). The predictive effect of adiponectin on 
cardiovascular diseases was initially documented in patients 
with end-stage renal disease (24). Recent study, with entry of 
18,000 US men, also reported that high adiponectin in plasma 
became a negative indicator for the incidence of myocardial 
infarction (25). In other study, hypoadiponectinemia was 
associated with an increased risk of 5-year mortality after 
ischemic stroke, independently (26). These clinical studies 
strengthened and confirmed the role of hypoadiponectinemia
in atherosclerosis.
Hypertension
Vascular endothelial dysfunction is a common feature of 
the MetS. Plasma adiponectin levels were significantly cor-
related with the forearm vasodilator response (27), suggest-
ing that hypoadiponectinemia might impair endothelium 
dependent vasodilation. Indeed, the acetylcholine, but not 
sodium nitroprusside, -induced vasorelaxation was impaired 
in adiponectin-deficient mice (28). Nitric oxide (NO) synthe-
sized by endothelial cells contributes to the vasodilatation. 
Adiponectin supplement activated AMP kinase and Akt, and 
subsequently phosphorylated endothelial NO synthase (29) in 
vascular endothelial cells. Michael Quon et al demonstrated 
that adiponectin enhanced the production of NO using high-
sensitive fluorescent method (30). Adiponectin deficiency in
mice developed high salt-induced hypertension (28). Further-
more, plasma adiponectin levels were inversely correlated with 
blood pressures in human subjects regardless with or without 
insulin resistance (31). Taken together, hypoadiponectinemia 
may, through disturbing NO production, contribute to the 
pathogenesis of hypertension in the MetS. 
Cardiac failure
Pressure overload by transverse aortic constriction caused 
severer concentric cardiac hypertrophy in the adiponectin 
deficient mice (32). The KO mice had smaller left ventricular 
cavity and died earlier. Supplement of adiponectin using 
adenovirus reversed the death rate to that of wild type mice. 
Adiponectin KO mice showed increased extracellular signal-
regulated kinase (ERK) and diminished AMP-activated protein 
kinase (AMPK) signaling in the myocardium. In cultures of 
cardiac myocytes, adiponectin activated AMPK and inhibited 
ERK activation. These results suggested that adiponectin 
should inhibit hypertrophic signaling in the myocardium 
through activating AMPK. Recent study also demonstrated that 
adiponectin protected ischemia-reperfusion injury in the heart 
of mice (33). Parts of these effects were considered mediation 
via AMPK and COX-2 pathways. 
Insulin resistance and diabetes
Plasma levels of adiponectin were lower in the diabetic pa-
tients even after BMI-matching, compared to non-diabetic 
subjects. Plasma adiponectin levels positively correlated with 
insulin sensitivity determined by glucose clamp in humans and 
non-human primates (34,35). Pima Indians with high plasma 
adiponectin at baseline exhibited lower risk of the newly 
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onset of diabetes (36). When APN-KO mice were fed with 
high-fat/high sucrose diet, KO mice exhibited higher plasma 
glucose and insulin levels, showing the characteristics of diet 
induced-insulin resistance and diabetes (37). These pheno-
types were reversed by the adenovirus-mediated supplement 
of adiponection. Tissue cultured and in vivo experiments 
revealed that adiponectin’s ability to enhance insulin action 
was attributed to its effect on liver and skeletal muscle, mainly 
through activating AMP-kinase pathway (38,39). 
Inflammation
The inflammatory process is common feature of the MetS and
involved in the development of CVD. The adipose tissue pro-
duces various proinflammatory cytokines such as interleukin-6 
(IL-6) and TNF-α, which are secreted into the circulation, and 
may accelerate the inflammatory process in vascular wall.
In vascular endothelial cells, adiponectin suppresses TNF-α 
signaling pathway and inhibits the expression of adhesion 
molecules (17,20). In macrophages, adiponectin specifically
and markedly suppresses the expression of TNF-α, and al-
most shut down the secretion of TNF-α from the cells (40). 
Interestingly, TNF-α also suppresses the expression and the 
secretion of adiponectin in adipocytes (37). Thus, TNF-α and 
adiponectin suppress the expression of each other. Recently, an 
inflammatory marker, high-sensitive CRP (hsCRP), was fea-
tured as a novel risk factor for both CVD and type 2 diabetes. 
Clinically, plasma levels of hsCRP correlated negatively with 
plasma adiponectin levels. In adiponectin KO mice, adipose 
expression of TNFα was augmented (37). Similarly, mRNACRP 
expression incresed in adipose tissue of adiponectin KO mice 
(41). In human, mRNACRP levels in fat correlated negatively 
with adiponectin mRNA levels (41). These data suggest that 
reduced expression of adiponectin induces the expression of 
CRP and TNFα in adipose tissue. In these negative loops be-
tween adiponectin and proinflammatory cytokines of CRP and
TNF-α, reduction of adiponectin should promote inflammatory
process locally in adipose tissue, and remotely in vascular wall, 
liver, skeletal muscle and other organs, which may underlie 
systemic low-grade inflammatory activity in MetS.
Plaque rupture is a major event in coronary heart disease. 
Macrophages take up oxidized LDL and form plaque lesions. 
Macrophages also produce various metalloproteinases and 
cause matrix degradation, leading to plaque rupture. Tissue 
inhibitor of metalloproteinase (TIMP-1) suppresses matrix 
metalloproteinase, and inhibits matrix degradation, leading 
to stabilize the plaque. We found that adiponectin induced 
mRNATIMP-1 expression in macrophages using the gene chip 
technique (42). We also showed that adiponectin suppressed 
the expression of scavenger receptor and inhibits plaque for-
mation. Taken together, adiponectin inhibits plaque formation 
and increases plaque stability, which should contribute to 
prevention of acute coronary syndromes.
Hepatic steatosis and liver injury 
The subjects with MetS often accompany fatty liver. Persist-
ence of fatty liver in obesity sometimes causes hepatic in-
flammation recently designated non-alcoholic steatohepatitis
(NASH). Collagen fibers in liver are synthesized by hepatic 
stellate cells. We showed that adiponectin significantly sup-
pressed PDGF-induced proliferation and TGF-β-induced 
collagen production in hepatic stellate cells (43). Adiponectin 
KO mice showed severer fibrosis induced by carbon tetra-
chloride compared to wild-type mice through the increase and 
activation of hepatic stellate cells (43). Such changes were 
canceled by the adiponecitn supplement by adenovirus. The 
pathogenesis of NASH and alcoholic liver injury is considered 
to involve gut-derived lipopolysaccharide (LPS). The complex 
of LPS and LPS-binding protein (LBP) activates Kupffer cells 
to secrete TNF-a, which plays an important role in liver injury. 
On the other hand, IL-10, which is secreted by Kupffer cells, 
has strong anti-inflammatory effects in the liver, and prevents
liver fibrosis. Our recent work showed that recombinant
adiponectin suppressed TNF-α production and induced IL-10 
production by Kupffer cells in response to LPS stimulation, and 
adiponectin deficiency in mice enhanced LPS-induced liver
injury associated with increased TNF-α  and reduced IL-10 
production (44). These results suggest hypoadiponectinemia 
should be one of upstreams of NASH and alcoholic liver in-
jury, and a therapeutic target for these pathologic conditions. 
Inflammatory bowel disease
It has been suggested that various immune, genetic, and envi-
ronmental factors influence both the initiation and progression
of inflammatory bowel diseases (IBD), such as ulcerative
colitis and Crohn’s disease. During the last half century, the 
incidence of IBD has markedly increased in the developed 
countries, which suggests that changes in lifestyle may con-
tribute to the development of IBD as well as obesity.
We recently investigated the effect of adiponectin on dex-
tran sulfate sodium (DSS)-induced colitis by using APN-KO 
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mice (45). Adiponectin-KO mice developed much severer 
colitis compared with WT mice. The mRNA expression levels 
of chemokines were significantly higher in the colon tissues
of DSS-treated APN-KO mice, accompanied by increased cel-
lular infiltration including macrophages.Adenovirus-mediated
supplement of adiponectin significantly attenuated the severity
of colitis. Recombinant adiponectin inhibited LPS-induced 
IL-8 production in intestinal epithelial cells. The results sug-
gested that hypoadiponectinemia may be involved in higher 
incidence of IBD in the developed countries. 
Cancer
Obesity and lifestyle such as physical inactivity, overnutrtion, 
and high fat-low dietary fiber diet are known to be associated
with breast, endometrial, prostatic and colon cancers. How-
ever, the molecular basis of the link remained unclear. We 
reported that low serum adiponectin levels were associated 
with an increased risk and biologically aggressive phenotype of 
breast cancer in human subjects (46). Mantzoros et al (47) also 
found an inverse relation between serum adiponectin levels and 
the incident risk for breast cancer in postmenopausal women. 
A significant inverse association of adiponectin with occur-
rence of endometrial cancer was reported in a case-control 
study (48). Another study also showed that body mass index 
and adiponectin became independent risks for the incidence 
of endometrial cancer (49). Further, plasma adiponectin levels 
were lower in patients with prostate cancer, and negatively as-
sociated with the histologic grade and stage (50). Association 
between plasma adiponectin level and colorectal cancer was 
also studied in 18,225 men by prospective nested case-control 
study (51). Men with low plasma adiponectin levels had a 
higher risk of colorectal cancer than men with higher levels. 
In a mouse tumor model, adiponectin significantly inhibited
tumor growth, accompanied by decreased neovascularization 
and increased tumor cell apoptosis (52). Future studies are 
necessary to clarify causality and the mechanisms underlying 
hypoadiponectinemia and several cancers related to obesity.
Hypoadiponectinemia: a common basis of diseases 
caused by overnutrition
Analysis of genetic hypoadiponectinemia gave us further 
insight and confidence about the clinical significance of adi-
ponectin. We found several genetic mutations in adiponectin 
gene (53,54). Among them, we focused on missense mutation 
with substitution of isoleucine 164 to threonine in the globular 
domain. Subjects carrying this mutation showed disturbed se-
cretion of this mutant protein (55), had markedly lower plasma 
adiponectin levels, and revealed to be significantly prone to
hypertension, hyperlipidemia, diabetes, and atherosclerosis. 
This further suggests that hypoadiponectinemia should locate 
upstream of the MetS. 
THERAPEUTIC STRATEGY TO ENHANCE ADIPONECTIN 
SECRETION AND ACTION 
According to the clinical and experimental evidence of adi-
ponectin’s multipotential favorable effects on the MetS, it is 
expected to develop a new therapeutic strategy to tackle this 
disorder by enhancing adiponectin production and function. 
For instance, peroxisome proliferator-activated receptor gam-
ma (PPARγ) agonists, thiazolidinediones, have been shown to 
raise plasma adiponectin levels in human subjects (56). We 
revealed the existence of PPAR-responsive element (PPRE) 
in the human adiponectin gene promoter and the detailed 
transactivation machinery (57). We found the involvement 
of another transcriptional factor, liver receptor homologue-1 
(LRH-1) as a competence factor for full transactivation of hu-
man adiponectin gene. Liver receptor homologue-1 enhanced 
PPARγ-mediated transactivation through LRH-1 responsive 
element (LRH-RE) close to the PPRE in the adiponectin pro-
moter. The association of LRH-1 with PPARγ was strength-
ened by PGC-1. To our knowledge, cooperative induction 
by PPARγ and LRH-1 is known only in adiponectin gene. 
Thiazolidinediones are known to cause several unfavorable 
side effects which might be attributed to transactivation of 
multiple genes having PPRE in those promoters. Pinpoint 
targeting the cooperative machinery of PPARγ and LRH-1 may 
lead to the identification of compounds to enhance adiponectin
production selectively.
Adiponectin cDNA was initially identified as the most
abundantly expressed gene in human adipose tissue. Hence 
adiponectin is most abundantly synthesized in adipocytes. 
Previously, we showed that testosterone inhibited adiponectin 
secretion selectively without altering the mRNA expression of 
adiponectin and changing the secretion of other adipocytokine 
like leptin (58). Xu et al (59) also demonstrated the suppressive 
effect of testosterone on the secretion of adiponcetin, espe-
cially its high molecular weight form. To elucidate the unique 
machinery for adiponectin secretion in adipocytes (and also 
in other cell types) may lead to the discovery of adiponectin 
secretagogues with novel therapeutic potentials.
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FAT ROS: AN EMERGING LINK BETWEEN OBESITY  
AND HYPOADIPONECTIEMIA 
Recently, our group demonstrated that, in obese mice, produc-
tion of ROS increased selectively in accumulated fat but not 
in muscle, liver, and aorta (60). The increase of fat ROS was 
associated with augmented expression of NADPH oxidase 
and decreased expression of antioxidative enzymes such as 
Cu, Zn-superoxide dismutase and catalase in adipose tissue 
(60). We also demonstrated that increased ROS in obesity 
was causative for various dysregulations of adipocytokines, 
including decreased production of adiponectin. 
In our recent clinical work, visceral fat accumulation was 
the most potent determinant for systemic ROS in human 
subjects among various metabolic and body shape parameters 
(61). The results demonstrated that ROS is more produced in 
visceral fat accumulation, which may result in the develop-
ment of hypoadiponectinemia. In the search of the drugs to 
target fat ROS, we found that angiotensin II receptor blockers 
(ARBs) have the potent capability to reduce the production 
of fat ROS via attenuating the expression of NADPH oxidase 
(62). This suppressive effect of ARBs on fat ROS was accom-
panied by improvement of adipocytokine dysregulation, like 
hypoadiponectinemia and also insulin resistance. These results 
suggested that fat ROS should be a key upstream regulator for 
the pathogenesis of MetS and shed a new light on the way for 
effective diagnosis and cure of this syndrome. 
CONCLUSION
Metabolic syndrome is formed by the contribution of many 
factors in a multiplex cascade. To know the factors located 
more upstream and playing more crucial role is important 
from the aspect of prevention and cure. Our works and others 
revealed that visceral fat accumulation and the subsequent 
hypoadiponectinemia are centered in the whole pathogenesis. 
Furthermore, our recent works showed that fat ROS should 
be a missing link between obesity and hypoadiponectinemia 
(Fig. 3). Moreover, lifestyle intervention and/or drug therapy 
that target visceral fat accumulation, hypoadiponectinemia 
and fat ROS should be intensively sought to tackle the MetS 
being prevailed worldwide.
Figure 3. Fat-derived reactive oxygen species (Fat ROS) is an emerging link between visceral fat accumulation and hypoadi-
ponectinemia. Increased ROS in visceral fat accumulation should lead to dysregulated production of adipocytokines, including 
hypoadiponectinemia. Dysregulated adipocytokinemia and increased ROS in blood stream should cause the pathogenesis of 
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